Breast Cancer | Specialty

Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1

January 13th 2021

Palbociclib Fails to Improve PFS in HR+, AI-Resistant Metastatic Breast Cancer

January 12th 2021

January 12, 2021 - Palbociclib in combination with endocrine therapy failed to result in a statistically significant improvement in progression-free survival over capecitabine in patients with hormone receptor–positive metastatic breast cancer who were resistant to aromatase inhibitors.

Practicing Outside the Pharma Box in Breast Cancer

January 9th 2021

Martine J. Piccart discusses her journey into the breast cancer treatment space.

More Innovation Is on Tap for 2021: Five Experts Describe Key Trends

January 8th 2021

The development of additional molecularly targeted therapies and the search for enhanced immunotherapy regimens are expected to permeate the oncology landscape across a broad range of malignancies as 2021 unfolds.

Dr. Hurvitz on the Expanding Metastatic HER2+ Breast Cancer Treatment Arsenal

January 7th 2021

Sara A. Hurvitz, MD, discusses the expanding HER2-positive metastatic breast cancer treatment arsenal.

Dr. O'Shaughnessy on the Rationale for the MonarchE Trial in Breast Cancer

January 7th 2021

Joyce A. O'Shaughnessy, MD, discusses the rationale for the monarchE trial in breast cancer.

Updated ExteNET Data Raise Questions Over TKI Utility in HER2+ Breast Cancer Brain Metastases and the Future of Neratinib

January 6th 2021

Adam M. Brufsky, MD, PhD, discusses the updated findings from the ExteNET trial, the role of TKIs in treating patients with brain metastases, and unanswered questions that future research efforts should aim to address.

FDA Grants Fast Track Status to ADC ARX788 for HER2+ Metastatic Breast Cancer

January 5th 2021

January 5th, 2021 -The FDA has granted a fast track designation to the investigational antibody-drug conjugate ARX788 for use as a monotherapy in the treatment of patients with advanced or metastatic HER2-positive breast cancer who have previously received 1 or more HER2-targeted regimens in the metastatic setting.

Novel CDK4/6 Inhibitor ON 123300 Receives Green Light to Move Into Phase 1 Testing in Relapsed/Refractory Advanced Cancers

January 5th 2021

January 5, 2021 – The FDA has granted permission for a phase 1 study evaluating ON 123300, a first-in-class multikinase CDK4/6 inhibitor to proceed under the agent’s investigational new drug application.

Homing in on HER2-Targeted Treatment Strategies in Early and Advanced Breast Cancer

January 5th 2021

Clinical risk continues to guide treatment decisions in early-stage HER2-positive breast cancer. The presence of brain metastases has become a driving force for treatment selection in the metastatic setting.